STOCK TITAN

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) CEO to Speak at Noble Capital Markets Healthcare Conference. Atossa is a clinical stage biopharmaceutical company focusing on breast cancer treatments.
Positive
  • None.
Negative
  • None.

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration. A video replay of the presentation will be available for 90 days following the event on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com


FAQ

When will the Atossa CEO speak at the Noble Capital Markets Healthcare Conference?

The Atossa CEO, Steven Quay, will speak on Wednesday, April 17 at 9:00 am ET.

What is the focus of Atossa Therapeutics?

Atossa is focusing on developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Where can individuals register to view the live presentation?

Individuals can register for the free event at Noble Healthcare Conference Registration.

Where can a video replay of the presentation be viewed?

A video replay will be available for 90 days on Atossa's investor relations page: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com.

Atossa Therapeutics, Inc.

NASDAQ:ATOS

ATOS Rankings

ATOS Latest News

ATOS Stock Data

190.46M
117.48M
0.06%
12.98%
8.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SEATTLE

About ATOS

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.